Anti-Diabetic and Hepato-Renal Protective Effects of Ziyuglycoside II Methyl Ester in Type 2 Diabetic Mice

Nutrients

Dong Ju Son¹  Seock Yeon Hwang³  Myung-Hyun Kim²  Un Kyu Park³ 

[1] College of Pharmacy & Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 361-951, Korea; E-Mail:;Department of Physiology, College of Korean Medicine, Daejeon University, Daejeon 300-716, Korea; E-Mail:;Department of Biomedical Laboratory Science, College of Natural Science, Daejeon University, Daejeon 300-716, Korea; E-Mails:

关键词: ziyuglycoside;    Sanguisorba officinalis;    diabetes;    diabetic hepatopathy;    diabetic nephropathy;   

DOI  :  10.3390/nu7075232

来源: mdpi

【 摘 要 】

Type 2 diabetes is a metabolic disorder caused by abnormal carbohydrate metabolism, and closely associated with abnormal lipid metabolism and hepato-renal dysfunction. This study investigated the anti-diabetic and hepato-renal protective properties of ziyuglycoside I (ZG01) derivative on type 2 diabetes. ZG01 was isolated from roots of Sanguisorba officinalis and chemically modified by deglycosylation and esterification to obtained ziyuglycoside II methyl ester (ZG02-ME). Here, we showed that ZG02-ME has stronger anti-diabetic activity than the original compound (ZG01) through decreasing blood glucose, glycated hemoglobin (HbA1c), and insulin levels in a mouse model of type 2 diabetes (db/db mice). We further found that ZG02-ME treatment effectively ameliorated serum insulin, leptin and C-peptide levels, which are key metabolic hormones, in db/db mice. In addition, we showed that elevated basal blood lipid levels were decreased by ZG02-ME treatment in db/db mice. Furthermore, treatment of ZG02-ME significantly decreased serum AST, ALT, BUN, creatinine, and liver lipid peroxidation in db/db mice. These results demonstrated that compared to ZG01, chemically modified ZG02-ME possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.